|Inovio's Synthetic DNA Vaccine Protects Against HIV In Non Human Primates.|
|By Staff and Wire Reports|
|Tuesday, 05 July 2011 19:31|
Inovio Pharmaceuticals, Inc. (AMEX:INO) announced data from a preclinical study of its SynCon™ DNA vaccine against HIV were published in two separate scientific journals. The studies, in vaccinated animals, demonstrated Inovio's HIV vaccine's ability to harness the power of the immune system, generating unique immune system responses, significant antigen-specific T-cell responses, and protection from the virus.
In the first study, the investigators generated a synthetic, optimized DNA vaccine encoding for a HIV envelope clade C protein utilizing Inovio's SynCon™ vaccine design process. Further optimization processes were conducted including codon/RNA optimization, and addition of a Kozak sequence and IgE sequence to enhance the expression of the vaccine in humans.
When assessed in rigorous tests, this vaccine construct generated robust and high levels of T cell responses that were up to three times greater than T cell responses from other comparable DNA vaccine constructs targeting HIV envelope.
Developing a vaccine for clade C is considered to be a very high priority since this clade or sub-type of HIV virus is prevalent in many parts of Africa, India, and China.
Two phase I human studies will test the immunogenicity of this vaccine in human volunteers in the U.S. and in Africa. In the second study, the investigators assessed the protective effects of Inovio's PENNVAX™ HIV DNA vaccines by examining an equivalent vaccine for the corresponding monkey virus, called SIV.
Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced today that they are collaborating with the National Aeronautics and Space Administration (NASA) Ames Research Center to conduct a preclinical test of a sclerostin antibody in an experiment that will take place aboard space shuttle Atlantis, on the final NASA shuttle mission, Space Shuttle Flight STS-135, scheduled to launch July 8, 2011.
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, helped raise funds with other teams and riders that totaled over $1.5 million during the 20th annual Napa Valley Tour de Cure, which took place on May 1 to benefit the American Diabetes Association.
Cord Blood America, Inc. (OTC Bulletin Board:CBAI) announced today it has entered into an agreement with Regence (www.regence.com/index.jsp) to offer the storage of umbilical cord blood to members of its BlueCross and BlueShield plans in Idaho, Oregon, Utah and Washington at a discount rate consistent with its other BlueCross BlueShield (BCBS) licensee contracts.
D. Medical Industries Ltd. (NASDAQ:DMED) (TASE:DMED) ("D. Medical" or the "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced today that its subsidiary, Spring Health Solutions Ltd. ("Spring Health"), has signed a non-binding letter of intent with Dex Medical, Canada's largest distributor of diabetes care products, to become exclusive distributor of the Spring Universal Infusion Set in Canada.
Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today announced that it has engaged Congressman Curt Weldon to assist in supporting the strategic development plan unveiled by the Company at a press conference in New York City on March 30, 2011.
Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced Laszlo Radvanyi, Ph.D., an Associate Professor in the Department of Melanoma Medical Oncology Research at the University of Texas MD Anderson Cancer Center in Houston, has joined its Scientific and Medical Advisory Board.
JC Data Solutions (PINKSHEETS: JCDS), a provider of innovative and cost-effective solutions for digital data processing and management focusing on the Oil & Gas, Legal and Healthcare industries, is pleased with past year's growth and their newly enhanced website www.jcdata.com.
Ken Glynn, President and CEO of GreenSmart Stores and Kenergy Scientific, Inc. (PINKSHEETS: KNSCD), today reported the status of various healthcare division projects.
Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced the completion of its first round of zinc finger micro-insertions.
MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials including bioimplants processed from human amniotic membrane, announced today that the Company's $5,000,000 private placement offering to sell common stock and warrants has been over-subscribed.
MMRGlobal, Inc. (OTCBB: MMRF) today announced that PCS International, Inc., a Texas-based reseller of cellular and related wireless products and services, has entered into a distribution agreement with MMRGlobal to sell MMRPro, the Company's document management and imaging system, to healthcare professionals, small hospitals, clinics, surgery centers, law firms and accountants. PCS will also offer the MyMedicalRecords Personal Health Record (www.mmrvideos.com) direct to consumers in 11 retail locations as an upgrade to other wireless offerings, including Smartphones and Tablet PCs.
Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ:ONCY) ("Oncolytics") today announced the appointment of George M. Gill, MD as Chief Medical Officer. He has been Senior Vice President of Clinical Safety and Regulatory Affairs and an officer of Oncolytics since 2002.
ProPhase Labs, Inc. (NASDAQ: PRPH) www.ProPhaseLabs.com ("ProPhase Labs" or the "Company") today announced that it received a letter from The Nasdaq Stock Market indicating that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Rule") because the closing bid price per share of its common stock has been below $1.00 per share for 30 consecutive trading days.
Unity Management Group, Inc. (OTC: UYMG) "UNITY" (or the "Company") (MCC) Metropolitan Computing Corporation has received authorization for a second purchase order to come in this week from Bristol Meyers Squibb, BMS Pharmaceuticals LTD., one of the largest pharmaceutical companies ,for $108,000.00.